about
O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patientsInhibition of O6-methylguanine-DNA methyltransferase by an alkyltransferase-like protein from Escherichia coli.Recurrent Glioblastoma: Where we standTowards in vivo amplification: Overcoming hurdles in the use of hematopoietic stem cells in transplantation and gene therapyContemporary murine models in preclinical astrocytoma drug developmentMiR-221/222 target the DNA methyltransferase MGMT in glioma cellsInter-individual variation in DNA repair capacity: a need for multi-pathway functional assays to promote translational DNA repair researchFluorogenic Real-Time Reporters of DNA Repair by MGMT, a Clinical Predictor of Antitumor Drug ResponseAdvances in chemical carcinogenesis: a historical review and prospectiveRestoration of sensitivity in chemo-resistant glioma cells by cold atmospheric plasma.Dose finding and O6-alkylguanine-DNA alkyltransferase study of cisplatin combined with temozolomide in paediatric solid malignancies.Temozolomide: a milestone in neuro-oncology and beyond?Temozolomide in children with progressive low-grade glioma.The role of gene body cytosine modifications in MGMT expression and sensitivity to temozolomide.Tumor O(6)-methylguanine-DNA methyltransferase inactivation by oral lomeguatrib.MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression.Promoter hypermethylation of MGMT gene may contribute to the pathogenesis of gastric cancer: A PRISMA-compliant meta-analysis.Influence of phosphate and phosphoesters on the decomposition pathway of 1,2-bis(methylsulfonyl)-1-(2-chloroethyhydrazine (90CE), the active anticancer moiety generated by Laromustine, KS119, and KS119WO6-Methylguanine-DNA methyltransferase protein expression by immunohistochemistry in brain and non-brain systemic tumours: systematic review and meta-analysis of correlation with methylation-specific polymerase chain reaction.Lethality to leukemia cell lines of DNA interstrand cross-links generated by Cloretazine derived alkylating species.Insight into the cooperative DNA binding of the O⁶-alkylguanine DNA alkyltransferase.Evaluation of O6-methylguanine-DNA methyltransferase enzyme expression effect on survival of patients with Grade 4 brain astrocytomaIn vivo enrichment of genetically manipulated platelets corrects the murine hemophilic phenotype and induces immune tolerance even using a low multiplicity of infectionInfluence of glutathione and glutathione S-transferases on DNA interstrand cross-link formation by 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)hydrazine, the active anticancer moiety generated by laromustine.Repair of O6-methylguanine adducts in human telomeric G-quadruplex DNA by O6-alkylguanine-DNA alkyltransferase.Prognostic prediction of glioblastoma by quantitative assessment of the methylation status of the entire MGMT promoter region.Quantitative relationship between guanine O(6)-alkyl lesions produced by Onrigin™ and tumor resistance by O(6)-alkylguanine-DNA alkyltransferase.Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study.Expression of O-Alkylguanine-DNA Alkyltransferase in Normal and Malignant Bladder Tissue of Egyptian PatientsSide population cells from human melanoma tumors reveal diverse mechanisms for chemoresistance.Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer.High activity of sequential low dose chemo-modulating Temozolomide in combination with Fotemustine in metastatic melanoma. A feasibility study.O6-methylguanine induces altered proteins at the level of transcription in human cellsA genome-wide miRNA screen revealed miR-603 as a MGMT-regulating miRNA in glioblastomas.Temozolomide in malignant gliomaFuture directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting.Patients with high-grade gliomas harboring deletions of chromosomes 9p and 10q benefit from temozolomide treatment.O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors.Leveraging metabolomics to assess the next generation of temozolomide-based therapeutic approaches for glioblastomasSelective inhibition of DNA replicase assembly by a non-natural nucleotide: exploiting the structural diversity of ATP-binding sites
P2860
Q24607903-37F876E8-5656-47A8-A621-B53BCADAE12BQ24811063-3AEE8726-9CEC-4BA0-A457-2D9EAAC0510EQ26765042-0CB0EB54-3664-44C4-B392-E822143803DBQ26771159-8B9FDA4D-0A4E-47D7-8C31-B3750CFCEA77Q27026937-56CD6708-4B25-46A5-B169-17B7E2553E71Q28118866-38DEBE24-BB41-459A-96EF-1DD0C6AE6019Q28388726-28E7F545-6970-4765-9371-C0CDE8A50140Q28551141-77B22CC8-91BB-4BF1-A7D2-5EA1EF60426FQ28756544-EFE622AB-1538-4C89-B0D9-927113C25FD7Q31118089-95FA089B-532B-4427-BDA4-F90D42845EFCQ33368246-6AD87011-BACD-4852-88FB-8F01AE47134AQ33372340-02C57A1C-041A-47D7-80D3-D01FC5C5295EQ33374472-8A032470-7CBA-4000-A0A0-D2FF6BEF0F62Q33578787-8DD8B341-877C-4FC5-A1C8-C9523ED3EF16Q33595174-D61CF134-9494-4CEA-A376-3AED5BD08F1BQ33618467-53979480-DE6C-4D05-B4AD-B2C51E3C1943Q33627145-E4F6B45D-B84A-406C-B5C1-F28A1791EA53Q33662290-34663EF2-4BF0-4C9D-AAF2-5DF80026C2B6Q33804528-90C1BDAA-9349-49B6-8537-102A6393FF7BQ33924789-719E0CC1-EC5E-43C2-8804-AC04CF428D08Q33954253-F37786E4-F452-466C-88A1-4BCEC8EFC700Q33977312-27F7CC63-05AB-4CB1-A998-CEB1AF77E373Q34021880-D1A2273A-7F93-4BE2-88AB-1D48B0D437E0Q34065933-2D9EB62C-53E5-4F54-AB00-5B9790C877B0Q34115421-46783C39-E9FA-44FE-9AE9-2B6377E29F52Q34168829-D4C11C2A-758F-4352-BD46-D4F95A5D951FQ34178990-9620DBFE-BAF5-40E5-B380-5CC4DF5F59D7Q34186787-D99EA5EA-0C6D-4EA0-8E35-FC4B2F96D4AAQ34218598-9D9FC7C9-FDAE-492F-933A-9ED255041966Q34279342-686F4C3D-19A6-4058-A0F1-62C6BF3C1976Q34288659-F9ED13B7-EE93-4804-992C-BC7C3DB83220Q34353577-EACF2212-D176-43DD-B151-B859FE1B667EQ34401442-725E7E9A-E399-4ADE-ABE7-4BF09BBB0B17Q34427825-ED72DFC9-FFF3-4E3A-A717-2D8A6E3BD9CDQ34623633-FEDB91C4-DDA4-4F44-BD2D-8D48B1D36BF3Q34743520-83AAFEF1-5BEB-4B2D-9444-ED9AA56E7F5DQ34769937-9EA2076E-F854-4C97-9F1E-B5CD2CE2BBDBQ35001754-DE2CCBB3-D867-4ED8-A293-AE52746266F7Q35171890-89F5ED91-4DA1-4B3D-92B6-98242026E7D3Q35203594-3371CF5B-D792-48A0-9A65-14A84DCF4F62
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Clinical relevance of MGMT in the treatment of cancer.
@ast
Clinical relevance of MGMT in the treatment of cancer.
@en
Clinical relevance of MGMT in the treatment of cancer.
@nl
type
label
Clinical relevance of MGMT in the treatment of cancer.
@ast
Clinical relevance of MGMT in the treatment of cancer.
@en
Clinical relevance of MGMT in the treatment of cancer.
@nl
prefLabel
Clinical relevance of MGMT in the treatment of cancer.
@ast
Clinical relevance of MGMT in the treatment of cancer.
@en
Clinical relevance of MGMT in the treatment of cancer.
@nl
P356
P1476
Clinical relevance of MGMT in the treatment of cancer.
@en
P2093
Stanton L Gerson
P304
P356
10.1200/JCO.2002.06.110
P407
P577
2002-05-01T00:00:00Z